Amgen Inc. operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Amgen Inc. with three other
companies in this sector in UNITED STATES :
sales of $5.70 billion
of which 78%
Gilead Sciences, Inc.
of which 100%
Amgen Inc. reported sales of $23.36 billion
December of 2019.
decrease of 1.6%
versus 2018, when the company's sales were $23.75 billion.
Contributing to the drop in overall sales was the 68.9% decline
in Sensipar, from $1.77 billion to $551.00 million.
There were also decreases in sales in
Neulasta (down 28.0% to $3.22 billion)
Aranesp (down 7.9% to $1.73 billion)
Other Revenues (down 4.6% to $1.16 billion)
Epogen (down 14.2% to $867.00 million)
However, these declines were partially offset by the increase in sales of
Enbrel (up 4.2% to $5.23 billion)
Other Products (up 15.2% to $4.96 billion)
Prolia (up 16.6% to $2.67 billion)
Xgeva (up 8.3% to $1.94 billion)